Clinical trials: Residual
Mantle Cell Lymphoma
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
This is a multi-arm phase 2 study to evaluate the preliminary evidence of efficacy and safety of the combination of acalabrutinib, lenalidomide and rituximab (ALR) and acalabrutinib, lenalidomide and obinutuzumab (ALO) in…
- Trial name
- NCT03863184
- Testing
- Acalabrutinib, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Weill Medical College of Cornell University
High Grade Meningioma
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
This research study is studying a drug as a possible treatment for High Grade Meningioma. The drug involved in this study is an immunotherapy drug called pembrolizumab
- Trial name
- NCT03279692
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes
Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes
This project is designed to study the role of vitamin D supplementation on the honeymoon phase of type 1 diabetes in children who are on standardized insulin treatment.
- Trial name
- PCR (NCT03046927)
- Testing
- Ergocalciferol
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Benjamin U. Nwosu, MD
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to…
- Trial name
- STRENGTH (NCT02104817)
- Testing
- Epanova® (omega-3 carboxylic acids), corn oil control
- Where
- 684 sites in United States, Australia and 20 more
- Volunteers
- 13,078 people
- Sponsor
- AstraZeneca
Healthy Subjects, Sleep Initiation and Maintenance Disorders
An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.
This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.
- Trial name
- NCT00699608
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nasopharyngeal Carcinoma
NBI to Detect Post-RT Mucosal Residual NPC
NBI has been proven to be a useful tool to detect early NPC, but they were few studies concerning the detection of post-radiotherapy mucosal residual NPC using NBI system
- Trial name
- NCT02584790
- Testing
- Laryngoscope with NBI system
- Where
- Hong Kong
- Volunteers
- 55 people
- Sponsor
- Pamela Youde Nethersole Eastern Hospital
Mucositis
Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690
Patients will receive methotrexate at a dose of 45 mg/m2 administered weekly for 4 consecutive weeks as an iv infusion along with a nutritional supplement administered two hours before the methotrexate.
- Trial name
- TK112690 (NCT04046250)
- Testing
- TK-112690
- Where
- 3 sites in India
- Volunteers
- 22 people
- Sponsor
- Tosk, Inc.
Acute Myeloid Leukemia (AML)
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR<0.05) AML (FLT3…
- Trial name
- NCT03512197
- Testing
- Midostaurin, Chemotherapy
- Where
- 133 sites in United States, Argentina and 18 more
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.
This study aims to test the effect of a newly-approved stimulant medication, lisdexamfetamine dimesylate (Vyvanse), on specific residual symptoms of depression found in some patients who are undergoing treatment with, but have…
- Trial name
- NCT01148979
- Testing
- Lisdexamfetamine Dimesylate (Vyvanse)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mclean Hospital
High Frequency Sensorineural Hearing Impairment, Hearing Disorders in Children
Outcomes in Children With Pre-operative Residual Hearing
Purpose: Routine clinical care and pilot study data has shown evidence of postoperative hearing preservation in pediatric cochlear implant (CI) recipients.
- Trial name
- NCT03379870
- Testing
- Electric Acoustic Speech Processor: Electric-acoustic stimulation fitting, Electric Acoustic Speech Processor: Full-electric stimulation fitting
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Glioblastoma Multiforme of the Brain
Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme
RATIONALE: Current therapies for Glioblastoma Multiforme provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of brain tumors.
- Trial name
- NCT00003474
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Burzynski Research Institute
Obstructive Sleep Apnea, Hypopnea
Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)
The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea…
- Trial name
- NCT00078325
- Testing
- Armodafinil 250 mg/day, Armodafinil 150 mg/day
- Volunteers
- 395 people
- Sponsor
- Cephalon
Schizophrenia
High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms
The primary aims of this study are to assess tolerability of ziprasidone dose escalation to 320 milligrams per day (mg/d) compared to continued standard treatment (placebo) as measured by the Side Effect Checklist, Simpson Angus…
- Trial name
- HDZ (NCT00403546)
- Testing
- Ziprasidone 80-160 mg/d, Ziprasidone 160 mg/d
- Where
- 9 sites in United States
- Volunteers
- 131 people
- Sponsor
- Donald C. Goff, MD
Residual Neuromuscular Blockade, Residual Paralysis, Post-Anesthesia
Incidence of Postoperative Residual Neuromuscular Blockade in Portugal
This is an epidemiological multicenter, observational, prospective study, designed to determine the incidence of postoperative residual neuromuscular blockade - defined by a TOF (train-of-four) ratio < 0.9 - at PACU arrival.
- Conditions
- Residual Neuromuscular Blockade, Residual Paralysis, Post-Anesthesia, Observational Study, Complication of Anesthesia
- Trial name
- NCT03417804
- Where
- 10 sites in Portugal
- Volunteers
- 366 people
- Sponsor
- Centro Hospitalar do Porto
Neuromuscular Blockade
Incidence of Incomplete Postoperative Neuromuscular Recovery From Anesthesia (P07535)(Completed)
This is a multicenter, observational study in adult participants undergoing different types of elective surgical procedures requiring general anesthesia.
- Trial name
- INSPIRE (NCT01181349)
- Testing
- Neuromuscular Blocking Agent (NMBA)
- Volunteers
- 350 people
- Sponsor
- Merck Sharp & Dohme LLC
Lenses, Intraocular
Tolerance to Residual Astigmatism in Eyes With Vivity®
Low amounts of postoperative residual astigmatism may worsen the visual performance of patients implanted with presbyopia- correcting intraocular lenses (IOLs).
- Trial name
- NCT05392998
- Testing
- Cataract surgery with Vivity intraocular lens implantation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Clínica Rementería
Urinary Incontinence
Bladder Scan of Residual Urine With New Catheter
Male intermittent catheters (ICs) range from 340-500 mm long, with the European standard minimum length being 360 mm for a catheter without a balloon and 275 mm for one with a balloon.
- Trial name
- NCT01048541
- Testing
- Test Catheter - SpeediCath Compact Male, SpeediCath
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Coloplast A/S
Leukemia, Acute Lymphoblastic
CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
This is a single center, single arm, open-label phase 2 study to determine the efficacy of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains…
- Trial name
- NCT02935543
- Testing
- CART 19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Pennsylvania
Neonatal Screening
The Effect of Electronic Informed Consent Information (EICI) on Residual Newborn Specimen Research
Obtaining adequate informed consent from potential research participants is a significant challenge for biobank-dependent research.
- Trial name
- EICI (NCT03141307)
- Testing
- EICI Movie, EICI App, Control
- Where
- United States
- Volunteers
- 711 people, healthy volunteers welcome
- Sponsor
- University of Utah
Sensorineural Hearing Loss, Low-Frequency Residual Hearing
Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing
The purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the CI632 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.
- Trial name
- NCT04741009
- Testing
- CI632 Slim Modiolar Electrode
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Cochlear